VRTX
VRTX clinical trials: VERTEX PHARMACEUTICALS INC / MA
Every trial on ClinicalTrials.gov where VERTEX PHARMACEUTICALS INC / MA is the lead sponsor or a listed collaborator, the trials it leads first, each labelled Lead or Collaborator. Phase, status and dates as registered.
- 298
- Trials linked
- 252
- As lead sponsor
- 46
- As collaborator
- 4
- Primary completions as lead sponsor, next 90 days
VRTX on the catalyst calendar · VRTX registry changes
- Primary completion Dec 12, 2027Sponsor estimatePhase 3NCT07890909A Phase 3b Study of Participant Experience on Povetacicept Administered Via Autoinjector as Compared to Sibeprenlimab Administered Via...Vertex Pharmaceuticals Incorporated · Immunoglobulin A NephropathyRecruitingVRTXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jun 27, 2029Sponsor estimatePhase 2/Phase 3NCT07204275Evaluation of Efficacy, Safety, and Tolerability of Povetacicept in Participants With Primary Membranous Nephropathy (pMN)Vertex Pharmaceuticals Incorporated · Primary Membranous NephropathyRecruitingVRTXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jan 25, 2027Sponsor estimatePhase 3NCT06696443Evaluation of the Long-term Safety and Effectiveness of Suzetrigine (SUZ) in Participants With Painful Diabetic Peripheral Neuropathy (DPN)Vertex Pharmaceuticals Incorporated · Diabetic Peripheral Neuropathic PainActive, not recruitingVRTXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 31, 2026Sponsor estimateNo phase registeredNCT06747572Polycystic Kidney Disease 1 (PKD1) Gene Variant Groups in Autosomal Dominant Polycystic Kidney DiseaseVertex Pharmaceuticals Incorporated · Autosomal Dominant Polycystic Kidney Disease (ADPKD)Active, not recruitingVRTXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Oct 12, 2026ActualPhase 4NCT07538570Evaluation of Pain Treatment After Total Knee ArthroplastyVertex Pharmaceuticals Incorporated · PainCompletedVRTXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 15, 2026Sponsor estimatePhase 1NCT07868926Absorption, Distribution, Metabolism, and Excretion of 14C-VX-407 After a Single Oral DoseVertex Pharmaceuticals Incorporated · Autosomal Dominant Polycystic Kidney Disease (ADPKD)RecruitingVRTXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Mar 2, 2029Sponsor estimatePhase 2NCT07501702A Phase 2 Study to Evaluate Povetacicept in Adults With Generalized Myasthenia GravisVertex Pharmaceuticals Incorporated · Myasthenia Gravis, GeneralizedActive, not recruitingVRTXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Oct 27, 2026Sponsor estimatePhase 1NCT07813039A Phase 1 Relative Bioavailability Study of a VX-581 Tablet FormulationVertex Pharmaceuticals Incorporated · Cystic FibrosisActive, not recruitingVRTXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Oct 27, 2025ActualPhase 4NCT06887959A Single-arm Study Evaluating the Effectiveness and Safety of Suzetrigine (SUZ) for Acute Pain After Selected SurgeriesVertex Pharmaceuticals Incorporated · Acute PainCompletedVRTXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Oct 24, 2025ActualPhase 4NCT06887972A Single-Arm Study Evaluating the Effectiveness and Safety of Suzetrigine (SUZ) for Acute Pain After Aesthetic or Reconstructive SurgeriesVertex Pharmaceuticals Incorporated · Acute PainCompletedVRTXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Apr 6, 2027Sponsor estimatePhase 3NCT05331183Study to Evaluate Elexacaftor/Tezacaftor/Ivacaftor (ELX/TEZ/IVA) Long-term Safety and Efficacy in Subjects Without F508delVertex Pharmaceuticals Incorporated · Cystic FibrosisActive, not recruitingVRTXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jun 2, 2028Sponsor estimatePhase 2/Phase 3NCT05312879Phase 2/3 Adaptive Study of VX-147 in Adult and Pediatric Participants With APOL1-Mediated Proteinuric Kidney DiseaseVertex Pharmaceuticals Incorporated · Proteinuric Kidney DiseaseActive, not recruitingVRTXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion May 31, 2027Sponsor estimatePhase 3NCT06628908Evaluation of Efficacy and Safety of Suzetrigine for Pain Associated With Diabetic Peripheral NeuropathyVertex Pharmaceuticals Incorporated · Diabetic Peripheral Neuropathic PainRecruitingVRTXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Sep 4, 2025ActualPhase 3NCT05882357Evaluation of Elexacaftor/Tezacaftor/Ivacaftor (ELX/TEZ/IVA) in Cystic Fibrosis (CF) Participants 12 to Less Than 24 Months of AgeVertex Pharmaceuticals Incorporated · Cystic FibrosisCompletedVRTXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 28, 2029Sponsor estimatePhase 3NCT07807995A Phase 3 Open-Label Study of Long-term Treatment With Povetacicept in Adults With Immunoglobulin A NephropathyVertex Pharmaceuticals Incorporated · Immunoglobulin A NephropathyEnrolling by invitationVRTXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jul 12, 2027Sponsor estimatePhase 1NCT07283770Evaluation of VX-581 in Healthy Participants and in Participants With Cystic FibrosisVertex Pharmaceuticals Incorporated · Cystic FibrosisRecruitingVRTXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jan 30, 2029Sponsor estimatePhase 2NCT06926621A Study of Long-term Safety and Efficacy of VX-670 in Participants With Myotonic Dystrophy Type IVertex Pharmaceuticals Incorporated · Myotonic Dystrophy Type 1 (DM1)Enrolling by invitationVRTXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Apr 21, 2026ActualPhase 1/Phase 2NCT05668741A Phase 1/2 Study of VX-522 in Participants With Cystic Fibrosis (CF)Vertex Pharmaceuticals Incorporated · Cystic FibrosisCompletedVRTXLeadMRNACollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Mar 12, 2027Sponsor estimatePhase 1/Phase 2NCT05791201A Safety, Tolerability, and Efficacy Study of VX-264 in Participants With Type 1 DiabetesVertex Pharmaceuticals Incorporated · Type 1 DiabetesActive, not recruitingVRTXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Oct 30, 2026Sponsor estimatePhase 3NCT05444257A Study Evaluating the Long-term Safety and Efficacy of VX-121 Combination TherapyVertex Pharmaceuticals Incorporated · Cystic FibrosisActive, not recruitingVRTXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Mar 11, 2027Sponsor estimatePhase 1NCT07792408Effects of VX-407 on the Pharmacokinetics of Combined Oral ContraceptivesVertex Pharmaceuticals Incorporated · Autosomal Dominant Polycystic Kidney Disease (ADPKD)RecruitingVRTXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jun 26, 2027Sponsor estimatePhase 1NCT07437105Dose Escalation Study Evaluating the Safety and Pharmacokinetics of VX-272 in Healthy ParticipantsVertex Pharmaceuticals Incorporated · Cystic FibrosisRecruitingVRTXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jul 22, 2027Sponsor estimatePhase 2NCT07161037Phase 2a Study of VX-407 in Participants With ADPKD Who Have a Subset of PKD1 Gene Variants (AGLOW)Vertex Pharmaceuticals Incorporated · Autosomal Dominant Polycystic Kidney Disease (ADPKD)Active, not recruitingVRTXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Aug 12, 2026ActualPhase 1/Phase 2NCT05757570An Open-label Study of Povetacicept in Participants With Autoimmune Cytopenias (RUBY-4)Alpine Immune Sciences Inc, A Subsidiary of Vertex · Idiopathic Thrombocytopenic PurpuraCompletedVRTXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Aug 17, 2026ActualPhase 1NCT07378865Evaluation of the Excretion of Suzetrigine Into Breast Milk in Healthy Lactating Female ParticipantsVertex Pharmaceuticals Incorporated · PainCompletedVRTXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
Enrollment, interventions and the start and completion dates are locked on 25 rows here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.
Unlock with TrialScannerShowing the first 25 trials. There are 273 more in this window; the full list is part of TrialScanner.
Unlock with TrialScanner